Restart Life Sciences (TSE:HEAL)
:HEAL
Want to see TSE:HEAL full AI Analyst Report?
HEAL Stock Chart & Stats
C$0.11
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.11
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.14
Previous CloseN/A
Volume800.00
Average Volume (3M)3.65K
Market Cap
C$5.94M
Enterprise ValueC$2.30M
Total Cash (Recent Filing)C$1.65M
Total Debt (Recent Filing)C$245.36K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding59,377,354
10 Day Avg. Volume5,146
30 Day Avg. Volume3,650
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementPositive equity in 2025 and relatively low debt materially reduce near-term solvency risk and improve financing flexibility. This durable change gives management more options for R&D funding or partnerships over the next several months without immediate distress-driven dilution.
Asset Base RebuildingA meaningful rebound in total assets versus prior years indicates the company is restoring its operating and investment capacity. A rebuilt asset base strengthens collateral for financing and supports sustained program development and operational recovery over a multi-month horizon.
Improving Cash Outflow TrendOperating and free cash outflows have narrowed versus the trough years, showing progress in reducing burn. While still negative, the improvement extends runway and lowers near-term external funding pressure, enabling more predictable execution of clinical or operational milestones.
Bears Say
No Recurring RevenueEffectively zero revenue across 2021–2025 means the company lacks a stable business model to self-fund operations. Over a 2–6 month horizon this necessitates continued external financing or partnership dependence and prevents internal cash generation from supporting growth.
Persistent Negative Cash FlowContinued negative operating and free cash flow signals structural cash burn rather than a short blip. This durable weakness forces reliance on external capital, increases dilution risk, and can constrain R&D pacing or program advancement if funding conditions tighten over the coming months.
Historical Equity VolatilityPrior periods of negative equity and volatility impair financing flexibility and raise solvency concerns with lenders and partners. That legacy makes raising capital more costly or conditional, limiting strategic options and increasing execution risk over the medium term.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.06 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$5.94M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Jun 02, 2026 which is in 7 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 59,377,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Technical Analysis
―
Entheon Biomedical
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Options Prices
Currently, No data available
---